BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 23333935)

  • 1. A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity.
    Yu X; Guo C; Yi H; Qian J; Fisher PB; Subjeck JR; Wang XY
    Cancer Res; 2013 Apr; 73(7):2093-103. PubMed ID: 23333935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLRC4-dependent antitumor immunity.
    Yu X; Liu W; Chen S; Cheng X; Paez PA; Sun T; Yuan F; Wei C; Landry JW; Poklepovic AS; Bear HD; Subjeck JR; Repasky E; Guo C; Wang XY
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracellular targeting of endoplasmic reticulum chaperone glucose-regulated protein 170 enhances tumor immunity to a poorly immunogenic melanoma.
    Wang XY; Arnouk H; Chen X; Kazim L; Repasky EA; Subjeck JR
    J Immunol; 2006 Aug; 177(3):1543-51. PubMed ID: 16849461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with tumor-derived ER chaperone grp170 elicits tumor-specific CD8+ T-cell responses and reduces pulmonary metastatic disease.
    Wang XY; Kazim L; Repasky EA; Subjeck JR
    Int J Cancer; 2003 Jun; 105(2):226-31. PubMed ID: 12673684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp100.
    Wang XY; Chen X; Manjili MH; Repasky E; Henderson R; Subjeck JR
    Cancer Res; 2003 May; 63(10):2553-60. PubMed ID: 12750279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the immunoregulator SRA/CD204 potentiates specific dendritic cell vaccine-induced T-cell response and antitumor immunity.
    Yi H; Guo C; Yu X; Gao P; Qian J; Zuo D; Manjili MH; Fisher PB; Subjeck JR; Wang XY
    Cancer Res; 2011 Nov; 71(21):6611-20. PubMed ID: 21914786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD204 suppresses large heat shock protein-facilitated priming of tumor antigen gp100-specific T cells and chaperone vaccine activity against mouse melanoma.
    Qian J; Yi H; Guo C; Yu X; Zuo D; Chen X; Kane JM; Repasky EA; Subjeck JR; Wang XY
    J Immunol; 2011 Sep; 187(6):2905-14. PubMed ID: 21832164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice.
    Okada N; Masunaga Y; Okada Y; Mizuguchi H; Iiyama S; Mori N; Sasaki A; Nakagawa S; Mayumi T; Hayakawa T; Fujita T; Yamamoto A
    Gene Ther; 2003 Oct; 10(22):1891-902. PubMed ID: 14502218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by Mycobacterium tuberculosis heat shock protein X.
    Jung ID; Shin SJ; Lee MG; Kang TH; Han HD; Lee SJ; Kim WS; Kim HM; Park WS; Kim HW; Yun CH; Lee EK; Wu TC; Park YM
    J Immunol; 2014 Aug; 193(3):1233-45. PubMed ID: 24990079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secretable chaperone Grp170 enhances therapeutic activity of a novel tumor suppressor, mda-7/IL-24.
    Gao P; Sun X; Chen X; Wang Y; Foster BA; Subjeck J; Fisher PB; Wang XY
    Cancer Res; 2008 May; 68(10):3890-8. PubMed ID: 18483274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superior antitumor response induced by large stress protein chaperoned protein antigen compared with peptide antigen.
    Wang XY; Sun X; Chen X; Facciponte J; Repasky EA; Kane J; Subjeck JR
    J Immunol; 2010 Jun; 184(11):6309-19. PubMed ID: 20439916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo.
    Wu YG; Wu GZ; Wang L; Zhang YY; Li Z; Li DC
    Med Oncol; 2010 Sep; 27(3):736-42. PubMed ID: 19669608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
    Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
    Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
    Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
    J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
    Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
    Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-metastatic immunotherapy based on mucosal administration of flagellin and immunomodulatory P10.
    de Melo FM; Braga CJ; Pereira FV; Maricato JT; Origassa CS; Souza MF; Melo AC; Silva P; Tomaz SL; Gimenes KP; Scutti JA; Juliano MA; Zamboni DS; Câmara NO; Travassos LR; Ferreira LC; Rodrigues EG
    Immunol Cell Biol; 2015 Jan; 93(1):86-98. PubMed ID: 25223833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.